Literature DB >> 12615407

Pulmonary administration of IgG loaded liposomes for passive immunoprophylaxy.

C Dreffier1, F Ramisse, C Dubernet.   

Abstract

Local passive immunoprophylaxy has been used in pulmonary infectious diseases successfully. However, the short immunoglobulins half-life in the lungs limits the duration of their action. The aim of the present study was to evaluate the efficiency of human polyvalent intravenous immunoglobulins (IVIG) when protected after encapsulation within EPC: DPPG liposomes by dehydration/rehydration. Two IVIG concentrations were chosen: 10 and 1 mg/ml for further studies in mice infected by influenza A. For the highest concentration (10 mg/ml), IVIG loaded liposomes did not significantly differ from IVIG/unloaded liposomes mixture with around 45% association yield. For the lowest concentration (1 mg/ml), two thirds of the IVIG associated were found inside the vesicles. In vivo, IVIG administered intranasally at 10 mg/ml (500 microg per mouse) 4 days before the infection led to 100% survival whatever the formulation. When administered at a lower dose (1 mg/ml-50 microg per mouse) 2 days before the challenge, loaded liposomes were found less efficient than free IVIG while unloaded liposomes showed a slight aspecific immunoprotection. Gastrointestinal clearance must be responsible for a major loss of liposomes compared to IVIG solution because of a higher viscosity of the formulation. Discrepancies with the literature are discussed. Copyright 2002 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12615407     DOI: 10.1016/s0378-5173(02)00680-4

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  3 in total

Review 1.  Passive broad-spectrum influenza immunoprophylaxis.

Authors:  Cassandra M Berry; William J Penhale; Mark Y Sangster
Journal:  Influenza Res Treat       Date:  2014-09-22

2.  Modulation of innate immune responses by influenza-specific ovine polyclonal antibodies used for prophylaxis.

Authors:  Catherine Rinaldi; William J Penhale; Philip A Stumbles; Guan Tay; Cassandra M Berry
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

Review 3.  Intravenous immunoglobulin for infectious diseases: back to the pre-antibiotic and passive prophylaxis era?

Authors:  Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Michel D Kazatchkine; Srini V Kaveri
Journal:  Trends Pharmacol Sci       Date:  2004-06       Impact factor: 14.819

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.